Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Madrigal Pharmaceuticals ( (MDGL) ) just unveiled an update.
On June 20, 2025, Madrigal Pharmaceuticals held its 2025 Annual Meeting of Stockholders where key decisions were made. The stockholders re-elected four Class III directors to serve until 2028, ratified PricewaterhouseCoopers LLP as the independent public accounting firm for 2025, and approved executive compensation policies. Additionally, it was decided that advisory votes on executive compensation will be held annually.
The most recent analyst rating on (MDGL) stock is a Buy with a $390.00 price target. To see the full list of analyst forecasts on Madrigal Pharmaceuticals stock, see the MDGL Stock Forecast page.
Spark’s Take on MDGL Stock
According to Spark, TipRanks’ AI Analyst, MDGL is a Neutral.
Madrigal Pharmaceuticals presents a mixed investment case. Strong revenue growth and a successful product launch boost its appeal, but profitability remains a challenge due to high operational costs. The stable balance sheet offers some reassurance, though ongoing cash burn and external financing reliance are risks. Technical indicators suggest a neutral stance with potential for growth, while the valuation reflects the high-risk nature typical of biotech firms.
To see Spark’s full report on MDGL stock, click here.
More about Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of innovative therapies for cardiovascular, metabolic, and liver diseases.
Average Trading Volume: 331,297
Technical Sentiment Signal: Buy
Current Market Cap: $6.28B
Find detailed analytics on MDGL stock on TipRanks’ Stock Analysis page.